{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:13Z","timestamp":1792701613450,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"crossref","award":["40896"],"award-info":[{"award-number":["40896"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rome IV bowel disorders of gut brain interaction (DGBI) and non-alcoholic fatty liver disease (NAFLD) are highly prevalent entities with overlapping pathophysiology and risk factors. We aimed to evaluate the prevalence and burden of Rome IV irritable bowel syndrome (IBS) in patients with NAFLD. Patients diagnosed with NAFLD were recruited from a specialist liver clinic. All participants completed assessments to determine liver fibrosis severity, including liver stiffness measurement (LSM), completed the Rome IV diagnostic questionnaire for bowel disorders of gut brain interaction, the IBS symptom severity score (IBS-SSS), and the EQ-5D-5L to measure of quality-of-life (QoL). 142 patients with NAFLD (71 (50%) female, mean age 53.5 (SD\u2009\u00b1\u200914.9), BMI 35.2 (SD\u2009\u00b1\u20098.1) kg\/M<jats:sup>2<\/jats:sup>) were recruited. 79 (55.6%) patients met criteria for a Rome IV bowel DGBI, including 50 patients (35.2%) who met the criteria for IBS (mean IBS-SSS 277.2 (SD\u2009\u00b1\u2009131.5)). There was no difference in liver fibrosis scores between those with and without Rome IV IBS (FIB-4 scores <jats:italic>p<\/jats:italic>\u2009=\u20090.14, LSM <jats:italic>p<\/jats:italic>\u2009=\u20090.68). Patients with NAFLD and Rome IV IBS had significantly worse QoL scores (EQ-VAS <jats:italic>p<\/jats:italic>\u2009=\u20090.005 and EQ-5D-5L index <jats:italic>p<\/jats:italic>\u2009=\u20090.0007), impairment of usual activities of daily living (<jats:italic>p<\/jats:italic>\u2009=\u20090.012) and were more likely to report anxiety or depression (<jats:italic>p<\/jats:italic>\u2009=\u20090.038). Rome IV bowel DGBI such as IBS are highly prevalent in patients with NAFLD attending liver clinics and are associated with impaired QoL and psychosocial distress.<\/jats:p>","DOI":"10.1038\/s41598-023-35774-5","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:02:38Z","timestamp":1685466158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study"],"prefix":"10.1038","volume":"13","author":[{"given":"Huw","family":"Purssell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Piper","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-4038","authenticated-orcid":false,"given":"Neil","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh H.","family":"Vasant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-721X","authenticated-orcid":false,"given":"Varinder S.","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"12","key":"35774_CR1","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"M Le","year":"2022","unstructured":"Le, M. et al. 2019 Global NAFLD Prevalence: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20(12), 2809\u20132817 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"35774_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","volume":"58","author":"M Blachier","year":"2013","unstructured":"Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C. & Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 58(3), 593\u2013608 (2013).","journal-title":"J. Hepatol."},{"issue":"9","key":"35774_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69(9), 1691\u20131705 (2020).","journal-title":"Gut"},{"key":"35774_CR4","unstructured":"Public Health England. Liver Disease: All our health. https:\/\/www.gov.uk\/government\/publications\/liver-disease-applying-all-our-health\/liverdisease Public Health England (2020). Accessed 8 Dec 2022."},{"issue":"4","key":"35774_CR5","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population based observational studies. PLos Med. 17(4), e1003100 (2020).","journal-title":"PLos Med."},{"issue":"3","key":"35774_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-021-01377-5","volume":"21","author":"K Martin","year":"2021","unstructured":"Martin, K., Hatab, A., Athwal, V. S., Jokl, E. & Piper Hanley, K. Genetic contribution to Non-alcoholic fatty liver disease and prognostic implications. Curr. Diabetes Rep. 21(3), 8 (2021).","journal-title":"Curr. Diabetes Rep."},{"key":"35774_CR7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"BE Lacy","year":"2016","unstructured":"Lacy, B. E. et al. Bowel disorders. Gastroenterology 150, 1393\u20131407 (2016).","journal-title":"Gastroenterology"},{"key":"35774_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14574","author":"H Jaafari","year":"2023","unstructured":"Jaafari, H. et al. The National prevalence of disorders of Gut-Brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome Foundation Global Epidemiology Study. Neurogastroenterol. Motil. https:\/\/doi.org\/10.1111\/nmo.14574 (2023).","journal-title":"Neurogastroenterol. Motil."},{"key":"35774_CR9","doi-asserted-by":"publisher","first-page":"e000002","DOI":"10.1136\/bmjgast-2014-000002","volume":"1","author":"S Atarodi","year":"2015","unstructured":"Atarodi, S., Rafieian, S. & Whorwell, P. Faecal incontinence\u2014the hidden scourge of irritable bowel syndrome: A cross sectional study. BMJ Open Gastroenterol. 1, e000002 (2015).","journal-title":"BMJ Open Gastroenterol."},{"issue":"6","key":"35774_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S2468-1253(19)30348-6","volume":"5","author":"M Hearn","year":"2020","unstructured":"Hearn, M., Whorwell, P. J. & Vasant, D. H. Stigma and irritable bowel syndrome: A taboo subject?. Lancet Gastroenterol. Hepatol. 5(6), 607\u2013615 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"35774_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/apt.15325","volume":"50","author":"M Zamani","year":"2019","unstructured":"Zamani, M., Alizadeh-Tabari, S. & Zamani, V. Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol. Ther. 50(2), 132\u2013143 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"12","key":"35774_CR12","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.4254\/wjh.v13.i12.1816","volume":"13","author":"H Purssell","year":"2021","unstructured":"Purssell, H., Whorwell, P., Athwal, V. & Vasant, D. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence. World J. Hepatol. 13(12), 1816\u20131827 (2021).","journal-title":"World J. Hepatol."},{"issue":"33","key":"35774_CR13","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.3748\/wjg.v19.i33.5402","volume":"19","author":"A Scalera","year":"2013","unstructured":"Scalera, A., Di Minno, M. N. D. & Tarantino, G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. World J. Gastroenterol. 19(33), 5402\u20135420 (2013).","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"35774_CR14","doi-asserted-by":"publisher","first-page":"S1429","DOI":"10.1016\/S0016-5085(20)34239-6","volume":"158","author":"M Jones-Pauley","year":"2020","unstructured":"Jones-Pauley, M. et al. Mo1503 Irritable bowel syndrome symptoms in non-alcoholic fatty liver disease patients are an indicator of depression and anxiety. Gastroenterology 158(6), S1429 (2020).","journal-title":"Gastroenterology"},{"issue":"3","key":"35774_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.7869\/tg.118","volume":"34","author":"SP Singh","year":"2013","unstructured":"Singh, S. P. et al. Profile of patients with incidentally detected non-alcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Trop. Gastroenterol. 34(3), 144\u2013152 (2013).","journal-title":"Trop. Gastroenterol."},{"issue":"3","key":"35774_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.15171\/mejdd.2018.104","volume":"10","author":"P Arasteh","year":"2018","unstructured":"Arasteh, P. et al. A comprehensive look at irritable bowel syndrome and its associated factors considering the Rome IV criteria: A penalized smoothly clipped absolute deviation regression approach in the Pars Cohort Study. Middle East J. Dig. Dis. 10(3), 149\u2013159 (2018).","journal-title":"Middle East J. Dig. Dis."},{"issue":"3","key":"35774_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/GHE.1000163","volume":"3","author":"AF Hasanain","year":"2018","unstructured":"Hasanain, A. F., Abdel-Rahman, M. E., Ali, A. M. & Abdel-Aal, S. M. Nonalcoholic fatty liver disease among patients with irritable bowel syndrome: Prevalence and contribution to disease severity. Gastroenterol. Hepatol. Endosc. 3(3), 1\u20134 (2018).","journal-title":"Gastroenterol. Hepatol. Endosc."},{"key":"35774_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","volume":"67","author":"PN Newsome","year":"2018","unstructured":"Newsome, P. N. et al. Guidelines on the management of abnormal liver blood tests. Gut 67, 6\u201319 (2018).","journal-title":"Gut"},{"issue":"4","key":"35774_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: A non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45(4), 846\u2013854 (2007).","journal-title":"Hepatology"},{"issue":"6","key":"35774_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIB\/HCV co-infection. Hepatology 43(6), 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"35774_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2016.02.014","volume":"150","author":"O Palsson","year":"2016","unstructured":"Palsson, O. et al. Rome IV diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology 150, 1481\u20131491 (2016).","journal-title":"Gastroenterology"},{"issue":"2","key":"35774_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"C Francis","year":"1997","unstructured":"Francis, C., Morris, J. & Whorwell, P. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol. Ther. 11(2), 395\u2013402 (1997).","journal-title":"Aliment Pharmacol. Ther."},{"key":"35774_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12916-022-02460-8","volume":"20","author":"S Wu","year":"2022","unstructured":"Wu, S. et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: A prospective cohort study. BMC Med. 20, 262 (2022).","journal-title":"BMC Med."},{"issue":"10","key":"35774_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","volume":"5","author":"P Oka","year":"2020","unstructured":"Oka, P. et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and metanalysis. Lancet Gastroenterol. Hepatol. 5(10), 908\u2013917 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"35774_CR25","doi-asserted-by":"publisher","first-page":"e0211348","DOI":"10.1371\/journal.pone.0211348","volume":"14","author":"RN Appleby","year":"2019","unstructured":"Appleby, R. N. et al. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS ONE 14(1), e0211348 (2019).","journal-title":"PLoS ONE"},{"issue":"9","key":"35774_CR26","doi-asserted-by":"publisher","first-page":"e14347","DOI":"10.1111\/nmo.14347","volume":"34","author":"H Noble","year":"2022","unstructured":"Noble, H., Hasan, S. S., Whorwell, P. J. & Vasant, D. H. The symptom burden of irritable bowel syndrome in tertiary care during the COVID-19 pandemic. Neurogastroenterol. Motil. 34(9), e14347 (2022).","journal-title":"Neurogastroenterol. Motil."},{"issue":"2","key":"35774_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/fampra\/17.2.108","volume":"17","author":"M Dixon-Woods","year":"2000","unstructured":"Dixon-Woods, M. & Critchley, S. Medical and Lay views of irritable bowel syndrome. Fam. Pract. 17(2), 108\u2013113 (2000).","journal-title":"Fam. Pract."},{"key":"35774_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","volume":"70","author":"D Vasant","year":"2021","unstructured":"Vasant, D. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70, 1214\u20131240 (2021).","journal-title":"Gut"},{"key":"35774_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cgh.2015.09.031","volume":"14","author":"EJ Kamp","year":"2016","unstructured":"Kamp, E. J., Kane, J. S. & Ford, A. Irritable bowel syndrome and Microscopic colitis: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 14, 659\u2013668 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35774-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35774-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:06:18Z","timestamp":1685466378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35774-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35774"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35774-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8769"}}